Navigation Links
Diabetes Drugs Might Lower Risk of Lung Cancer

By Amanda Gardner
HealthDay Reporter

TUESDAY, Nov. 2 (HealthDay News) -- Researchers report that drugs used to treat diabetes may indeed both prevent and contain lung cancer.

The findings, being presented Tuesday at the annual meeting of the American College of Chest Physicians in Vancouver, back up preliminary data that some diabetes medications might protect against tobacco-induced lung cancer.

"Patients who did not develop lung cancer had a much higher chance of taking one of these medications than those who did develop lung cancer," said study author Dr. Peter Mazzone. "And those who did develop lung cancer were much less likely to have seen that cancer spread outside the chest and more likely to survive longer with one of these drugs."

Both metformin and the class of drugs known as thiazolidinediones (which includes Avandia and Actos) are used by tens of millions of Americans.

A mouse study published in September found that metformin was associated with up to a 73 percent reduction in the number of tumors mice developed when they were given a common carcinogen found in tobacco. The mice had been genetically engineered to be susceptible to this kind of tumor. Epidemiological studies in humans have found similar effects.

Metformin was originally marketed as Glucophage, but is now available as an inexpensive generic.

For this study, Mazzone and his colleagues reviewed and compared electronic medical records on 225 diabetics with lung cancer with a similar number of diabetic patients who did not have lung cancer, although both groups shared other risk factors such as age, smoking history and gender.

"Forty-one percent of those with lung cancer had taken one of these medications at some point prior to developing the cancer, and 96 percent of all the controls had taken one of these medications in diabetic treatment," reported Mazzone, director of the lung cancer program at The Respiratory Institute at the Cleveland Clinic in Ohio.

Of those with lung cancer, 25 percent of those who developed metastatic disease (which is disease that has spread) were taking one of the medications versus 48 percent of those who did not take one of the drugs.

Also, "the longer someone took the medication, the more protective it seemed to have been," Mazzone said. "This also supports the premise that these medications might be able to serve as risk modifiers."

But there's a long way to go before doctors can start recommending metformin, Avandia or Actos for otherwise healthy people to protect against lung cancer.

"There have been no direct studies using these medications in humans for the purpose of preventing or altering the course of lung cancer," Mazzone said. "We need to fully understand the mechanisms by which these medications might prevent or change the course of cancer. We need to develop large clinical trials using these medications and following people forward to see if they are protective, as retrospective studies have suggested."

And the safety profile of these drugs or similar compounds need to be investigated if the drugs are going to be used in non-diabetics, he said. For instance, both Avandia and Actos have been shown to raise the chances of developing certain cardiovascular risk factors.

"This is the sort of study that raises an interesting question that maybe there is some activity," added Dr. Lucas Wong, an associate professor of internal medicine at Texas A&M Health Science Center College of Medicine, co-director of the Gastrointestinal Cancer Program and principal investigator of the Community Clinical Oncology Program at Scott & White in Temple, Texas. "The harder thing is to figure out how to dose the medication, how to use, [but] just because you're a diabetic and you're taking this medication doesn't mean you're not going to get lung cancer."

It should be noted that research presented at meetings is not subject to the same scrutiny as peer-reviewed research published in respected journals.

More information

The U.S. National Library of Medicine has more on thiazolidinediones.

SOURCES: Peter Mazzone, M.D., director, lung cancer program, The Respiratory Institute, The Cleveland Clinic, Ohio; Lucas Wong, M.D., associate professor, internal medicine, Texas A&M Health Science Center College of Medicine, co-director, Gastrointestinal Cancer Program, and principal investigator, Community Clinical Oncology Program, Scott & White, Temple, Texas

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inhaled steroids increase diabetes risk, say Lady Davis Institute researchers
2. Insulin-creating cell research may lead to better diabetes treatment
3. Haptoglobin as an early serum biomarker of virus-induced type 1 diabetes in rats
4. One-Third of U.S. Adults Could Have Diabetes by 2050: CDC
5. Peer Support May Bring Better Control of Diabetes
6. Even Well-Controlled Diabetes May Present Post-Surgery Risk
7. Type 2 diabetes and insulin use are associated with colorectal cancer in men
8. Hospitalizations Way Up for Young Adults With Diabetes
9. Can Wii help control gestational diabetes?
10. Metabolic status before pregnancy predicts subsequent gestational diabetes
11. Diabetes gene linked to degeneration of enzyme involved in Alzheimers disease onset and progression
Post Your Comments:
Related Image:
Diabetes Drugs Might Lower Risk of Lung Cancer
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy ... and funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving ... things from patients including their ability to work and be productive, to do simple ...
(Date:12/1/2015)... ... 2015 , ... Henderson, a town of about 6,300 people, ... a partnership this year with Aeneas Internet and Telephone. , With faster Internet ... entrepreneurs who want to build a business. Whether startups or long established companies, ...
(Date:12/1/2015)... ... ... Integrated Rental Services (“Integrated Rental”), a growing medical equipment ... With support from JII, Integrated Rental is poised for expansion while improving its ... labs and medical facilities across the United States. , General Manager Robert Bean ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
Breaking Medicine Technology: